• Recently, Legend Biotech expanded its scientific advisory board with six leading experts in oncology and cell therapy and, together with Janssen, agreed to increase CARVYKTI manufacturing capacity at Janssen’s Raritan, New Jersey facility to support its cell therapy ambitions.
• This combination of deeper scientific guidance and scaled manufacturing marks a meaningful step in Legend’s efforts to build an end-to-end cell therapy platform targeting high unmet medical needs.
• We’ll now examine how the expanded CARVYKTI manufacturing agreement with Janssen could influence Legend Biotech’s existing investment narrative and outlook.

Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

Legend Biotech Investment Narrative Recap

To own Legend Biotech, you need to believe CARVYKTI can anchor a broader, durable cell therapy franchise while the company works toward profitability. In the near term, the key catalyst remains execution on CARVYKTI uptake, while the biggest risk is the product’s concentration and any disruption in supply or safety perception. The expanded Janssen manufacturing agreement directly targets supply risk, but it does not eliminate Legend’s dependence on a single asset.

Among recent updates, the agreement with Janssen to increase CARVYKTI capacity at the Raritan facility is most relevant here. It supports Legend’s push to match potential demand with reliable, scalable manufacturing, which is critical if CARVYKTI’s label expansions and geographic rollouts are to translate into revenue growth. At the same time, higher capacity can also reinforce the existing risk profile if market competition or pricing pressures limit how fully that capacity is used.

Yet investors should also weigh how increased CARVYKTI capacity might interact with future pricing pressure and reimbursement scrutiny that you should be aware of...

Legend Biotech's narrative projects $2.1 billion revenue and $501.1 million earnings by 2029.

Uncover how Legend Biotech's forecasts yield a $57.24 fair value, a 100% upside to its current price.

Exploring Other Perspectives

The most cautious analysts see a tougher road than consensus, with revenue only reaching about US$1.6 billion and earnings about US$69.7 million by 2029, reminding you that views on CARVYKTI’s long term pricing and reimbursement risk can differ sharply and that this Janssen manufacturing news could still reshape those expectations over time.

Explore 6 other fair value estimates on Legend Biotech - why the stock might be worth over 4x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Legend Biotech research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Legend Biotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Legend Biotech's overall financial health at a glance.

Looking For Alternative Opportunities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Find 51 companies with promising cash flow potential yet trading below their fair value.
• Capitalize on the AI infrastructure supercycle with our selection of the 40 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.